Process for producing solid oral dosage forms with sustained release of active ingredient

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 7413750
APP PUB NO 20020012701A1
SERIAL NO

09873431

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to a process for producing solid oral dosage forms with sustained release of active ingredient, comprising at least one active ingredient, a preformulated mixture of polyvinyl acetate and polyvinylpyrrolidone, where appropriate, water-soluble polymers or lipophilic additives and, where appropriate, other conventional excipients, wherein this mixture or parts of this mixture are granulated by heating to from 40.degree. C. to 130.degree. C., and the granules are, after admixture with conventional excipients, subsequently tabletted.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
BASF SELUDWIGSHAFEN2951

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Ascherl, Hermann Dirmstein, DE 16 221
Flick, Dieter Bohl-Iggelheim, DE 8 56
Kolter, Karl Limburgerhof, DE 100 678

Cited Art Landscape

Patent Info (Count) # Cites Year
 
SCHWARZ PHARMA AG (1)
5453283 Orally administered solvent-free pharmaceutical preparation with delayed active-substance release, and a method of preparing the preparation 22 1993
 
FARVALSA A.G. (1)
* 4837032 Theophylline sustained release tablet 18 1986
 
NOVARTIS AG (1)
5403593 Melt granulated compositions for preparing sustained release dosage forms 60 1992
 
HEXAL AG (1)
5874107 Sustained release tablet containing diclofenac-Na and methylhydroxypropyl-cellulose as a sustained release agent 1 1996
 
TANABE SEIYAKU CO., LTD. (1)
* 5389380 Sustained release pharmaceutical preparation and process for preparing the same 15 1993
 
AWD.PHARMA GMBH & CO. KG (1)
6103264 Process for preparing a controlled release composition 6 1998
 
DUQUESNE UNIVERSITY OF THE HOLY GHOST, A CORP. OF PA. (1)
5169645 Directly compressible granules having improved flow properties 158 1989
 
BASF AKTIENGESELLSCHAFT (2)
* 4801460 Preparation of solid pharmaceutical forms 133 1987
* 6635279 Active ingredient-containing floating forms comprising polyvinyl acetate and polyvinylpyrrolidone, their use and production 74 2001
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
Other [Check patent profile for assignment information] (1)
* 2009/0023,754 Modified release famciclovir pharmaceutical compositions 0 2006
 
HORIZON PHARMA AG (2)
* 2010/0222,312 DELAYED-RELEASE GLUCOCORTICOID TREATMENT OF ASTHMA 2 2010
* 2010/0196,427 DELAYED-RELEASE GLUCOCORTICOID TREATMENT OF RHEUMATOID ARTHRITIS BY IMPROVING SIGNS AND SYMPTOMS, SHOWING MAJOR OR COMPLETE CLINICAL RESPONSE AND BY PREVENTING FROM JOINT DAMAGE 2 2010
 
BASF SE (3)
* 2011/0195,118 Process for Producing Oral Dosage Forms With Controlled Release 4 2009
* 9439971 Use of polyether-based and vinyl monomer-based copolymers as binders for dosing forms comprising solid active ingredients 0 2013
* 2013/0123,373 Use Of Polyether-Based And Vinyl Monomer-Based Copolymers As Binders For Dosing Forms Comprising Solid Active Ingredients 0 2013
 
Eisai Research Institute (1)
* 2007/0129,402 Sustained release formulations 2 2006
 
Pharmaceutical Manufacturing Research Services, Inc. (1)
9492444 Extruded extended release abuse deterrent pill 0 2014
 
EISAI R&D MANAGEMENT CO., LTD. (3)
* 8481565 Method for stabilizing anti-dementia drug 0 2005
* 2009/0023,778 Composition Containing Anti-Dementia Drug 2 2006
8507527 Method for stabilizing anti-dementia drug 0 2010
 
HZNP LIMITED (2)
8920838 Delayed-release glucocorticoid treatment of rheumatoid disease 1 2013
9504699 Delayed-release glucocorticoid treatment of rheumatoid disease 0 2014
* Cited By Examiner

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Feb 19, 2020
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00